ESR1 and cancer: ESR1 mutations, which are common in patients who develop bone metastasis, enhance the adhesive properties of cancer cells, facilitating their colonization in the bone microenvironment, and are observed in approximately 30–40% of patients with metastatic endocrine-positive breast cancer, particularly those with hormone receptor-positive breast cancer [91].